Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

European Innovation Council · Running

CD20CARNAPT iTANK: a nuniversal technology to boost the efficacy of CAR T cell therapies by inducing dual mode-of-actio

Coordinator
Elicera Therapeutics AB, Sweden
Runs
1 October 2022 to 30 September 2025
Status
Running
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190129097

What the project is doing

In the project's own words, from its summary on CORDIS.

Elicera developed a universally compatible technology platform called iTANK (ImmunoTherapies Activated with NAP for efficient Killing) to enhance the efficacy of current and under development CAR-T cell therapies by inducing a dual mechanism-of-action in the treatment of lymphomas and solid tumours. Elicera’s iTANK platform can circumvent major challenges of CAR-T cells in the treatment of solid tumours, such as antigen heterogenicity, local immunosuppression, and CAR T-cell exhaustion.

As such, the iTANK platform has a potential to revolutionise the landscape of the immuno-oncologyOur innovation arms CAR-T cells with NAP from H.pylori which induces a pro-inflammatory microenvironment and activates the patient’s own CD8+ killer T-cells against the whole repertoire of relevant tumour antigen targets. When tumour cells are killed, NAP-activated dendritic cells can take up tumour-associated antigens and prime killer T-cells against these antigens overcoming problems for CAR-T therapy.

Topics

Who is involved

OrganisationCityCountryRole
Elicera Therapeutics ABGoteborgSwedenCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI